

NHS ENGLAND SPECIALISED SERVICES
CLINICAL PANEL REPORT

Date: October 2019

Intervention: Stereotactic ablative body radiotherapy (SABR)

Indication: previously irradiated para-aortic tumours

ID: 1918

Gateway: 2 Round: 2

Programme: Cancer

CRG: Radiotherapy

Information provided to the panel

Clinical Panel Report from Gateway 2 Round 1

Evidence Review by Kings' Technology Evaluation Centre (KiTEC)

KiTEC Evaluative Commissioning Report

Clinical Priorities Advisory Group Summary Report

Policy Proposition

Key elements discussed

This proposition is proposed as not for routine commissioning.

This was previously considered by Panel as part of a combined policy proposition for patients with previously irradiated, locally recurrent pelvic, spinal or para-aortic tumours. Panel considered that there was no evidence identified to support the routine commissioning of this specific indication. Therefore a not for routine commissioning policy proposition has now been submitted for consideration.

Clinical Panel reviewed the evidence base against the proposition and agreed that the recommended commissioning position was appropriate.

Panel considered that the description in the introduction needed rewording as rather cumbersome currently.

Recommendation

Clinical Panel recommended that this proposition progress as a not for routine commissioning policy proposition.

Why the panel made these recommendations

The Clinical Panel considered that the evidence base presented demonstrates there is no evidence for this indication.

Documentation amendments required

Policy Proposition:

- Revise the wording in the introduction to be clearer and succinct.
-

Declarations of Interest of Panel Members: None.

Panel Chair: James Palmer, Medical Director

Post Panel notes

Post Clinical Panel, the policy statement wording was amended as requested.